Diasome Pharmaceuticals Inc

Diasome Pharmaceuticals Inc

Managed Investment Scheme

Register Interest

The law normally requires people who offer financial products to give information to investors before they invest. This requires those offering financial products to have disclosed information that is important for investors to make an informed decision. The usual rules do not apply to this offer if you are a person who comes within Schedule 1, clause 3(2)(a)-(c) or 3(3)(a)-(b)(ii) (inclusive) of the Financial Markets Conduct Act 2013. This includes where the amount invested upfront by the investor (plus any other investments the Investor has already made in the financial products) is $750,000 or more.


If you fall within Schedule 1, clause 3 of the FMCA as a result of this exclusion, you may not receive a complete and balanced set of information. You will also have fewer other legal protections for this investment. Investments of this kind are not suitable for retail investors. Ask questions, read all documents carefully, and seek independent financial advice before committing yourself.

Transaction Size
USD $30,000,000.00
Share Price
Minimum Investment
USD $50,000.00
Issue Type
Managed Investment Scheme
Health Care

Syndex has been asked to seek Expressions of Interest from wholesale investors to participate in a capital raising for Diasome Pharmaceuticals Inc, an Ohio based Pharmaceuticals business that has developed an insulin delivery system/additive called Hepatic Directed Vesicle (HDV) insulin. 

This opportunity comes to us via our USA based partners that have previously introduced NZ investors into other US based pre-listing opportunities including Airbnb, SpaceX, Orchestra Biomed and a number of other Medtech opportunities.

HDV enables a portion of current insulin products to be directed to the liver, restoring the liver’s physiological role in glycemic equilibrium. This technology has been shown to significantly decrease hypoglycemic events in patients with diabetes, making it unique in the diabetes treatment space. HDV could also potentially improve overall glycemic control which, combined with it benefits in hypoglycemia, could provide a substantial advance in the treatment of diabetes. Investors will be investing alongside, and with the same terms as Eli Lily (LLY) who will also have a Right of First Refusal (ROFR) to buy the company outright.

A supporting pack is included in the Documents tab, which provides an overview of the solution Diosome can deliver. A link to the company website is here


Click on the tab to register interest and you will be contacted by an advisor to the company who can provide more information to support your analysis of the investment opportunity

FILE-2695 (4)
May 19, 2023

Join our Business/Issuer newsletter

Our quarterly Issuer newsletter is for businesses and issuers, and contains platform updates and business insights.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.